Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPB regimen for early extranodal NKT cell lymphoma
ChiCTR2200066349Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Dec 2022
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of asparaginase escherichia coli and bortezomib in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: objective response rate, complete remission rate and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
asparaginase escherichia colibortezomib
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR2200066349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066349.